BR112012008518A2 - derivado heterocíclico, e, composição farmacêutica - Google Patents

derivado heterocíclico, e, composição farmacêutica

Info

Publication number
BR112012008518A2
BR112012008518A2 BR112012008518A BR112012008518A BR112012008518A2 BR 112012008518 A2 BR112012008518 A2 BR 112012008518A2 BR 112012008518 A BR112012008518 A BR 112012008518A BR 112012008518 A BR112012008518 A BR 112012008518A BR 112012008518 A2 BR112012008518 A2 BR 112012008518A2
Authority
BR
Brazil
Prior art keywords
heterocyclic derivative
pharmaceutical composition
heterocyclic
present
derivative
Prior art date
Application number
BR112012008518A
Other languages
English (en)
Inventor
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Paul David Ratcliffe
Thomas Rusell Clarkson
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of BR112012008518A2 publication Critical patent/BR112012008518A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

derivado heterocíclico, e, composição farmacêutica. a presente invenção se refere a um derivado heterocíclico da fórmula (i) em que as variáveis são como definido na especificação ou um sal farmaceuticamente aceitável ou solvado do mesmo. a presente invenção ainda se refere ás composições farmacêuticas que compreendem os ditos derivados heterocíclicos e em uso em terapia, por exemplo, no tratamento ou prevenção das doenças mediadas pelos receptores acetilcolina nicotínicos, tal como esquizofrenia e mal de alzheimer.
BR112012008518A 2009-10-13 2010-10-11 derivado heterocíclico, e, composição farmacêutica BR112012008518A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
BR112012008518A2 true BR112012008518A2 (pt) 2016-04-05

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008518A BR112012008518A2 (pt) 2009-10-13 2010-10-11 derivado heterocíclico, e, composição farmacêutica

Country Status (12)

Country Link
US (1) US8841289B2 (pt)
EP (1) EP2488520B1 (pt)
JP (1) JP2013507417A (pt)
KR (1) KR20120100913A (pt)
CN (1) CN102666540A (pt)
AU (1) AU2010305825A1 (pt)
BR (1) BR112012008518A2 (pt)
CA (1) CA2776835A1 (pt)
IN (1) IN2012DN02968A (pt)
MX (1) MX2012004289A (pt)
RU (1) RU2012119488A (pt)
WO (1) WO2011045258A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018735A1 (ja) 2011-07-29 2013-02-07 大正製薬株式会社 アミジン化合物又はその塩
AU2013229229B2 (en) 2012-03-07 2017-10-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US20150164858A1 (en) * 2012-05-22 2015-06-18 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
NO3044221T3 (pt) 2013-09-11 2018-07-21
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
WO2016201096A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
ES2950348T3 (es) 2015-12-09 2023-10-09 Novartis Ag Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
WO2020004594A1 (ja) * 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
KR20210039368A (ko) 2018-07-26 2021-04-09 도메인 테라퓨틱스 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도
LT3830092T (lt) 2018-08-03 2023-09-11 Novartis Ag Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai
WO2021198188A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
MXPA03009650A (es) * 2001-04-20 2005-03-07 Vertex Pharma Derivados de 9-deazoguanidina como inhibidores de gsk-3.
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
AU2006274245B2 (en) * 2005-07-26 2011-11-24 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
CA2663161C (en) * 2006-09-11 2014-10-28 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
MX2010005040A (es) * 2007-11-14 2010-05-21 Neurosearch As Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil-pirimidina y su uso medico.
KR20100114123A (ko) 2008-02-29 2010-10-22 테크노 코어 인터내셔널 가부시키가이샤 팩 전지의 충전 장치 및 팩 전지의 품질 판정 장치

Also Published As

Publication number Publication date
KR20120100913A (ko) 2012-09-12
US20120208796A1 (en) 2012-08-16
IN2012DN02968A (pt) 2015-07-31
RU2012119488A (ru) 2013-11-20
US8841289B2 (en) 2014-09-23
EP2488520A1 (en) 2012-08-22
AU2010305825A1 (en) 2012-04-19
WO2011045258A1 (en) 2011-04-21
MX2012004289A (es) 2012-06-12
CA2776835A1 (en) 2011-04-21
CN102666540A (zh) 2012-09-12
EP2488520B1 (en) 2015-09-02
JP2013507417A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0811280B8 (pt) compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
BRPI1015568B8 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
BRPI0511874A (pt) derivados da pirrolopiridina
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
SV2011003855A (es) Heteroarilos sustituidos
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
UY29301A1 (es) Derivados amida
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
MX2011009847A (es) Agentes antihelminticos y su uso.
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
MX339644B (es) Sales de xantilio 3,6-disustituidas.
BR112012006387A2 (pt) aminas de triazol fundidas como moduladores de p2x7
MX2009013501A (es) Compuestos piperidinicos y sus usos.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]